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Summary 
Background Back pain remains a challenge for primary care internationally. One model that has not been tested is 
stratiﬁ cation of the management according to the patient’s prognosis (low, medium, or high risk). We compared the 
clinical eﬀ ectiveness and cost-eﬀ ectiveness of stratiﬁ ed primary care (intervention) with non-stratiﬁ ed current best 
practice (control).
Methods 1573 adults (aged ≥18 years) with back pain (with or without radiculopathy) consultations at ten general 
practices in England responded to invitations to attend an assessment clinic. Eligible participants were randomly 
assigned by use of computer-generated stratiﬁ ed blocks with a 2:1 ratio to intervention or control group. Primary 
outcome was the eﬀ ect of treatment on the Roland Morris Disability Questionnaire (RMDQ) score at 12 months. In 
the economic evaluation, we focused on estimating incremental quality-adjusted life years (QALYs) and health-care 
costs related to back pain. Analysis was by intention to treat. This study is registered, number ISRCTN37113406. 
Findings 851 patients were assigned to the intervention (n=568) and control groups (n=283). Overall, adjusted mean 
changes in RMDQ scores were signiﬁ cantly higher in the intervention group than in the control group at 4 months 
(4·7 [SD 5·9] vs 3·0 [5·9], between-group diﬀ erence 1·81 [95% CI 1·06–2·57]) and at 12 months (4·3 [6·4] vs 3·3 [6·2], 
1·06 [0·25–1·86]), equating to eﬀ ect sizes of 0·32 (0·19–0·45) and 0·19 (0·04–0·33), respectively. At 12 months, 
stratiﬁ ed care was associated with a mean increase in generic health beneﬁ t (0·039 additional QALYs) and cost savings 
(£240·01 vs £274·40) compared with the control group.
Interpretation The results show that a stratiﬁ ed approach, by use of prognostic screening with matched pathways, will 
have important implications for the future management of back pain in primary care.
Funding Arthritis Research UK. 
Introduction
Back pain remains a major international health problem, 
with a lifetime prevalence of 80–85%1 that poses substantial 
challenges for clinical management.2 For example, in the 
UK, each year 6–9% of adults consult their general 
practitioner about back pain,3 with only 20–40% no longer 
reporting pain or disability a year later.4 Therefore, 
improvement of the primary care management of low 
back pain has the potential to reduce the long-term eﬀ ects 
of back pain, including persistent disabling symptoms, 
low quality of life, and reduced capacity to work.5
Results of primary care trials6–9 show that more 
sophisticated treatments (such as manual treatments, 
exercise, and cognitive behavioural approaches) are more 
eﬀ ective than usual or minimal care of back pain. 
However, because of insuﬃ  cient evidence, guideline 
recommendations10 are not clear about the clinical 
selection of patients who are likely to beneﬁ t from 
additional interventions. Generally, for most patients 
with non-speciﬁ c back pain, initial referral decisions are 
based on clinical intuition despite evidence to suggest 
that this provides ineﬃ  cient and inconsistent access to 
treatment.11 The alternative option, referral of all patients 
with back pain for treatment, is generally thought to be 
unnecessary, impractical, and ineﬃ  cient because of the 
high numbers and costs.5,10–12
A one-size-ﬁ ts-all primary care strategy13 is suboptimum 
because it ignores the heterogeneity in patients.14 A novel 
approach, gaining interest in other medical specialties,15 
but not yet tested in the management of back pain, is to 
test whether stratiﬁ ed care according to the estimated risk 
of poor prognosis (deﬁ ned here as persistent disability 
because of back pain) improves clinical outcomes while 
remaining cost eﬀ ective. We developed a stratiﬁ ed model 
of primary care management of back pain,16 which consists 
of two complementary components. First, a previously 
validated, simple-to-use prognostic screening method (the 
Keele STarT Back Screening Tool),17–19 to allocate patients 
into one of three risk-deﬁ ned groups—low, medium, and 
high (webappendix p 1). Second, three treatment pathways, 
developed with clinical experts (webappendix p 2), were 
matched to these risk groups.16
In this trial, we test the main hypothesis that a stratiﬁ ed 
approach to primary care management for low back pain 
results in clinical and economic beneﬁ ts compared with 
current best practice. Our other aims were to test 
For the Keele STarT Back 
Screening Tool see http://www.
keele.ac.uk/startback
See Online for webappendix
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diﬀ erences within each of the three risk groups—for low-
risk patients, whether minimum treatment provided 
non-inferior clinical outcomes to current best care; for 
medium-risk patients, whether systematic referral to 
physiotherapy led to better clinical outcomes than did 
current best care; and for high-risk patients, whether 
systematic referral to psychologically augmented physio-
therapy led to better clinical outcomes than did current 
best care.
Methods
Participants
The methods are reported in full in the protocol.16 In ten 
general practices within the Keele General Practice 
Research Partnership, England, adults who had consulted 
their doctor about back pain during June, 2007, to 
November, 2008, were identiﬁ ed through weekly searches 
of electronic patients’ records for morbidity codes for back 
pain.16 Individuals who were identiﬁ ed were sent a letter 
from back pain referral services in two National Health 
Service (NHS) centres, with an invitation to telephone to 
make an appointment at the initial assessment clinic, 
information about the trial, and baseline questionnaires. 
At the clinic, a research nurse assessed patients for 
eligibility, obtained written informed consent, and 
checked completion of the questionnaire, including the 
STarT Back Screening Tool (webappendix p 1).17 Patients 
were included in the study if they were at least 18 years 
old, could speak and understand English, and had back 
pain of any duration, with or without associated 
radiculopathy. We excluded patients with potentially 
serious disorders (eg, cauda equina compression, 
inﬂ ammatory arthritis, and malignancy), serious illness 
or comorbidity (including those undergoing treatment 
for a prevalent axis 1 or 2 mental health disorder according 
to the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition [DSM-IV] criteria), who had 
spinal surgery in the past 6 months, who were pregnant, 
who were receiving back treatments (except primary care), 
and who were unable or unwilling to attend (ﬁ gure 1).
A trial steering and independent data monitoring 
committee oversaw the trial. The North Staﬀ ordshire 
Local Research Ethics Committee approved the protocol.
Randomisation and masking
A clinic administrator telephoned a remote clinical trials 
unit (Keele University), which assigned participants to 
intervention and control groups by use of computer-
generated stratiﬁ ed block randomisation (block sizes of 
three) in a 2:1 ratio to enable future secondary analysis 
of targeted treatment mechanisms. Stratiﬁ cation was 
accord ing to the NHS centre (n=2) and STarT Back 
Screening Tool risk subgroup. Participants, administrator, 
or physiotherapists could not be masked to randomisation 
because therapists were administering the active inter-
vention; however, we ensured that the therapists admin-
istering the control treatment were not made aware of the 
details of the stratiﬁ ed model of care during the trial, and 
that patients were made aware that they would be treated 
according to one of two primary care management models. 
The research nurse who retrieved outcome data was 
masked to randomisation, and the concealment strategies 
were that the nurse was in a separate oﬃ  ce during clinic, 
the administrator randomly assigned the patients, and the 
use of a masked follow-up database. 
Baseline clinical assessment and treatment
On the same day and in the same NHS centre as the 
nurse assessment, baseline clinical and treatment 
sessions were delivered to intervention and control groups 
by study physiotherapists. To guard against learning and 
contamination eﬀ ects, diﬀ erent physiotherapists (13 in 
the intervention group and 40 in the control group) 
delivered initial clinic and ongoing physiotherapy. 
Irrespective of the treatment group, participants were not 
restricted from using health care elsewhere or seeing 
their general practitioner during the follow-up.
In the control group, during the baseline clinical 
assessment and treatment session, decisions about 
referral were made on the basis of the physiotherapists’ 
clinical judgment, without knowledge of a participant’s 
STarT Back Tool classiﬁ cation. Participants received a 
30-min physiotherapy assessment and initial treatment 
including advice and exercises, with the option of onward 
referral to further physiotherapy. Control physiotherapists 
received a half day training to familiarise them with 
study procedures.
In the intervention group, during the baseline clinical 
assessment and treatment session, decisions about 
referral were made by use of the STarT Back Screening 
Tool classiﬁ cation. The 30-min assessment and initial 
treatment were delivered according to an agreed protocol, 
with advice focusing on promotion of appropriate levels 
of activity, including return to work, and a pamphlet 
about local exercise venues and self-help groups. 
Participants were shown a 15-min educational video 
entitled Get Back Active20 and given the Back Book.21 
Low-risk patients were only given this clinic session; 
medium-risk and high-risk patients were referred for 
further physiotherapy-led treat ment sessions. Clinic 
physiotherapists doing the assess ments in the inter-
vention group were given 1 day of training about the 
STarT Back Screening Tool, and to standardise advice 
and data gathering from the case report forms. 
Follow-up treatment sessions
In the control group, referral for further physio therapy was 
entirely at the clinical discretion of the physio thera pists 
delivering the baseline session. The physiotherapists to 
whom they could refer were in usual NHS practice settings 
and did not overlap with the physiotherapists providing 
follow-up sessions in the intervention group. Such 
physiotherapists have general training in physical therapies 
and some training in more complex psycho logically 
For the STarT Back trial protocol 
see http://www.ncbi.nlm.nih.
gov/pmc/articles/PMC2377248/
pdf/1471-2474-9-58.pdf
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informed treatments, but none underwent special training 
or instruction related to this study.
In the intervention group, medium-risk patients, 
according to the STarT Back Screening Tool, were referred 
for standardised physiotherapy to address symptoms and 
function. High-risk patients were referred for psycho-
logically informed physiotherapy to address physical 
symptoms and function, and also psychosocial obstacles 
to recovery. Physiotherapists delivering the medium-risk 
intervention were given 3 days of additional training, and 
those delivering the high-risk intervention had 6 days of 
additional training (ie, 9 days in total).
Outcomes
Demographic data and clinical outcomes were gathered 
before randomisation and 4 months and 12 months later 
by use of postal questionnaires. Case report forms were 
used to gather data about treatment content from the 
physiotherapists. The primary clinical outcome was the 
eﬀ ect of treatment on the Roland and Morris Disability 
75208 adults registered from 
 ten family doctor practices
70759 without back pain morbidity codes
 
4449 with back pain morbidity 
 codes
1656 excluded by family doctors because
 did not meet inclusion criteria
2793 sent postal invitations to 
 attend clinic for back pain
1220 did not respond 
 
1573 attended and assessed for 
 eligibility
60 did not have follow-up 
4 withdrawals
56 did not respond to 
questionnaire
102 did not have follow-up 
13 withdrawals
89 did not respond to 
questionnaire
503 did not consent
219 not eligible
 112 unable to attend
 58 already receiving treatment 
 32 language barrier
 9 serious comorbidity
 8 pregnant 
283 (33%) control group
 73 low risk (36 [49%] referred 
  for physiotherapy)
 131 medium risk (78 [60%] 
  referred for physiotherapy)
 79 high risk (51 [65%] referred 
  for physiotherapy)
568 (67%) intervention group
 148 low risk (11 [7%] referred 
  for physiotherapy)
 263 medium risk (259 [98%] 
  referred for physiotherapy)
 157 high risk (all referred for 
  physiotherapy)
466 (82%) 4-month follow-up
 118 (80%) low risk
 217 (83%) medium risk
 131 (83%) high risk
223 (79%) 4-month follow-up
 60 (82%) low risk
 106 (81%) medium risk
 57 (72%) high risk 14 did not have follow-up 
4 withdrawals
10 did not respond to 
questionnaire
26 did not have follow-up 
2 withdrawals
24 did not respond to 
questionnaire 440 (77%) 12-month follow-up
 110 (74%) low risk
 202 (77%) medium risk
 128 (82%) high risk
209 (74%) 12-month follow-up
 57 (78%) low risk
 96 (73%) medium risk
 56 (71%) high risk
568 assessed in intention-to-treat
 analysis
283 assessed in intention-to-treat
 analysis
851 randomly assigned
Figure 1: Trial proﬁ le
Two patients in the control group died during the study (one before 4-month follow-up and one before 12-month follow-up), one developed a serious comorbidity in 
the intervention group (before 4-month follow-up), and 20 contacted the National Health Service centre to withdraw from the study (14 in intervention group 
[12 before 4-month follow-up and two before 12-month follow-up] and six in control group [three before 4-month follow-up and three before 12-month follow-up]). 
At 4 months, 622 (90%) of 689 responders sent their responses in the post (419 [90%] of 466 in intervention group and 203 [91%] of 223 in control group); the 
remaining 67 (10%) responders supplied key outcome responses by telephone (47 [10%] in intervention group and 20 [9%] in control group). At 12 months, 
567 (87%) of 649 responders sent their responses in the post (386 [88%] of 440 in intervention group and 181 [87%] of 209 in control group); 82 (13%) of 
649 patients responded by telephone (54 [12%] in intervention group and 28 [13%] in control group). Of 689 responders at the 4-month follow-up, one patient in the 
control group did not complete the primary outcome measure (Roland and Morris Disability Questionnaire). 
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Questionnaire22 (RMDQ; scale 0–24; high scores indicate 
severe disability) score at 12 months. 
Descriptions and psychometric properties of the 
secondary outcome measures are reported in detail 
elsewhere.16 Secondary outcome measures were referral 
for further physiotherapy, back pain intensity, the Pain 
Catastrophizing Scale23 (measures the extent to which 
someone has a pessimistic outlook of back pain), fear-
avoidance beliefs (Tampa Scale of Kinesiophobia24), 
Hospital Anxiety and Depression Scale,25 health-related 
quality of life (EuroQol EQ-5D;26 Short Form 1227 physical 
and mental component scores), STarT Back Screening 
Tool risk-subgroup reduction, perception of overall 
change in back pain (global change), number of 
physiotherapy treatment sessions,  attendance at initial 
physiotherapy treatment, adverse events, health-care 
resource use and costs over 12 months, number of days 
oﬀ  work because of back pain, and satisfaction with care.
We did a telephone follow-up of non-responders at both 
timepoints for disability, and catastrophising and global 
changes. Adverse events were deﬁ ned as any serious 
morbidity or events causing unwarranted distress to a 
participant that were potentially related to either inter-
vention; information was gathered by the physiotherapists 
and from patients’ self-completed questionnaires.
Statistical analysis
The trial hypotheses were tested by use of pretreatment 
randomisation allocation to low-risk, medium-risk, and 
high-risk groups in the intervention and control groups. 
Since the secondary hypotheses to test diﬀ erences at a 
risk-group level required a larger sample size than did the 
primary hypothesis, we used this for our power calculation. 
Hence, the sample size calculation was based on the ability 
to detect, for high-risk and medium-risk groups, a 
between-treatment mean diﬀ erence of 2·5 RMDQ points 
at the 12-month primary endpoint with a 5% two-tailed 
signiﬁ cance level; and for the low-risk group, an equivalent 
one-tailed 2·5% level non-inferiority test. Allowing for a 
20% loss to follow-up, we aimed to recruit 800 participants. 
However, during recruitment, on the basis of the recom-
mendation by our trial data monitoring committee, this 
number was revised to 850 participants to compensate for 
a larger than anticipated loss at the 12-month follow-up of 
25%. Although powered to detect diﬀ erences in the 
low-risk, medium-risk, and high-risk groups, the revised 
total sample size provided 80% power to detect an overall 
treatment eﬀ ect size of 0·2, equivalent to a mean diﬀ erence 
in RMDQ scores between the intervention and control 
groups of about 1. 
Analysis was by intention to treat. For the primary 
analyses, imputed datasets were used for all descriptive 
and inferential assessments to address attrition bias, 
generated through multiple imputation (pooled estimates 
of ﬁ ve imputed datasets) by use of simulation based on a 
multivariate normal model (numerical variables) and a 
logistic regression model (categorical outcomes).28 
Estimates of treatment eﬀ ect (mean diﬀ erence for 
numerical outcomes, odds ratios for categorical outcomes, 
and incidence rate ratios for lost work days), with 95% CI, 
were obtained by use of linear, binary logistic, ordinal 
logistic, and Poisson regression models respectively, with 
adjustment for baseline score, age, sex, RMDQ, and back 
pain duration (as agreed a priori with our trial steering 
group). Standardised eﬀ ect sizes were reported, alongside 
numbers needed to treat (NNT) by use of at least 30% 
change in RMDQ;29 and calculation of 95% CI for NNT by 
use of Stang and colleagues’ recommendations.30 
Sensitivity analyses were done by use of complete-case 
analysis (ie, non-imputed dataset) and further adjustment 
for therapist’s eﬀ ects with random-eﬀ ects modelling of 
main therapist. All analyses were done with SPSS 
(version 17.0.1) and STATA (11.0). 
The analysis of cost-eﬀ ectiveness focused on estimation 
of mean incremental quality-adjusted life years (QALYs) 
and back-pain-related health-care costs for the overall 
stratiﬁ ed management approach by use of a within-trial 
analysis. QALYs were calculated with the EQ-5D. Details of 
the numbers of physiotherapy sessions attended by each 
participant were obtained through case report forms and 
an audit of clinical notes for the participating physiotherapy 
services. Other health-care costs were estimated from 
responses to the resource-use items contained within the 
12 month self-report questionnaire. Details of the unit 
costs applied to units of resource use are provided in 
webappendix p 5. Like the clinical analysis, the economic 
evaluation was replicated in the complete-case dataset.
To assess the economic consequences of the stratiﬁ ed 
management intervention beyond health-care resources, 
costs were also assigned to self-reported work absence by 
use of the human capital approach; self-reported work 
absence was weighted by respondent-speciﬁ c wage rates 
identiﬁ ed from data for yearly earnings and UK Standard 
Occupational Classiﬁ cation codes.31,32 Because of the 
12-month follow-up during the study, costs or health 
beneﬁ ts were not discounted.
This study is registered, number ISRCTN37113406.
Role of the funding source
Keele University sponsored the trial, approved the design, 
and appointed the trial steering and data monitoring 
committee. The funder was not involved in the 
preparation of the study protocol, management of the 
trial, analysis of the data, or preparation of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
Figure 1 shows the trial proﬁ le; 851 patients were 
randomly assigned to the intervention and control 
groups. The STarT Back Screening Tool classiﬁ ed 
221 (26%) patients as low risk, 394 (46%) as medium 
risk, and 236 (28%) as high risk in the intervention and 
For the UK Standard 
Occupation Classiﬁ cation see 
http://www.ons.gov.uk/ons/
guide-method/classiﬁ cations/
archived-standard-
classiﬁ cations/standard-
occupational-
classiﬁ cation-2000/
about-soc-2000/index.html
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control groups. The mean age of participants was 
50 years (range 18–87), and 500 (59%) of 851 patients 
were women. Table 1 shows the baseline characteristics 
of the participants. Baseline sex, disability, and duration 
of pain were similar for participants with data at 
12 months and those lost to follow-up. However, those 
lost to follow-up were younger: mean age of the 
individuals who responded at 12 months was 
52·0 years [SD 14·2] compared with 42·3 years [14·0] for 
those who did not respond. Responders at 12 months 
had a mean baseline RMDQ score of 9·8 [5·7] and non-
responders had a score of 9·8 [5·6]. 386 (59%) of 
649 responders and 114 (56%) of 202 non-responders at 
12 months were women. 95 (47%) non-responders 
versus 292 (45%) responders at 12 months had their 
pain for longer than 6 months. 
The mean number of total treatment sessions was 
similar in the intervention and control groups 
(3·9 [SD 2·6] vs 3·8 [3·6], respectively), although a 
higher proportion of patients in the intervention group 
were referred for further physiotherapy (427 [75%] of 
568 vs 165 [58%] of 283). In the intervention group, 
referral decisions were in agreement with those 
predicated by use of the STarT Back Screening Tool 
in 553 cases, but not in 15 cases—11 low-risk patients 
were referred and four medium-risk patients were not 
referred (ﬁ gure 1). This diﬀ erence arose because 
therapists were allowed to overrule the STarT Back 
Screening Tool recommendation if the clinician thought 
that the decision to overrule was appropriate. Referral 
patterns were substantially diﬀ erent in controls, with 
more than a third of medium-risk and high-risk patients 
not referred for physiotherapy, and about half of all low-
risk patients referred for treatment (ﬁ gure 1). Among 
the participants referred, initial treatment attendance 
was 528 (93%) in the intervention group and 263 (93%) 
in the control group, with those in the intervention 
group receiving fewer physiotherapy sessions (mean 
All participants Low-risk participants Medium-risk participants High–risk participants
Intervention 
group (n=568)
Control group 
(n=283)
Intervention 
group (n=148)
Control group 
(n=73)
Intervention 
group (n=263)
Control group 
(n=131)
Intervention 
group (n=157)
Control group 
(n=79)
Demographics
Age (years) 50·1 (15·0) 49·1 (14·3) 46·5 (14·3) 47·6 (14·7) 50·5 (15·3) 49·3 (13·5) 52·7 (14·5) 50·1 (15·3)
Sex, female 330 (58%) 170 (60%) 82 (55%) 42 (58%) 160 (61%) 83 (63%) 88 (56%) 45 (57%)
Routine and manual occupations* 287 (51%) 149 (53%) 61 (41%) 26 (36%) 137 (52%) 65 (50%) 89 (57%) 58 (73%)
Currently in paid employment 350 (62%) 174 (61%) 112 (76%) 50 (68%) 158 (60%) 83 (63%) 80 (51%) 41 (52%)
Time oﬀ  work for back pain† 185 (53%) 90 (52%) 40 (36%) 12 (24%) 95 (60%) 51 (61%) 50 (63%) 27 (66%)
Back pain and function
RMDQ disability score 9·8 (5·6) 9·7 (5·8) 4·6 (3·5) 4·2 (3·3) 9·9 (4·5) 9·8 (4·8) 14·4 (4·6) 14·7 (4·4)
Back pain intensity 5·3 (2·2) 5·2 (2·2) 3·4 (1·6) 3·5 (1·7) 5·5 (1·7) 5·3 (1·8) 7·0 (1·8) 6·8 (2·0)
Duration of back pain
<1 month 97 (17%) 54 (19%) 25 (17%) 14 (19%) 44 (17%) 24 (18%) 28 (18%) 16 (20%)
1–3 months 124 (22%) 66 (23%) 31 (21%) 15 (21%) 61 (23%) 39 (30%) 32 (20%) 12 (15%)
3–6 months 81 (14%) 42 (15%) 19 (13%) 12 (16%) 38 (14%) 16 (12%) 24 (15%) 14 (18%)
6 months to 3 years 144 (25%) 65 (23%) 45 (30%) 21 (29%) 65 (25%) 27 (21%) 34 (22%) 17 (22%)
>3 years 122 (21%) 56 (20%) 28 (19%) 11 (15%) 55 (21%) 25 (19%) 39 (25%) 20 (25%)
Radiating leg pain 352 (62%) 178 (63%) 61 (41%) 28 (38%) 176 (67%) 89 (68%) 115 (73%) 61 (77%)
Radiating pain below knee 179 (32%) 93 (33%) 24 (16%) 10 (14%) 75 (29%) 47 (36%) 80 (51%) 36 (46%)
Psychological measures
PCS, catastrophising score 16·3 (10·8) 15·9 (11·1) 8·6 (5·8) 8·1 (6·5) 14·6 (8·1) 13·6 (8·1) 26·4 (10·6) 26·9 (10·3)
PCS ≥20 186 (33%) 89 (31%) 8 (5%) 4 (5%) 60 (23%) 28 (21%) 118 (75%) 57 (72%)
TSK, fear avoidance score 40·3 (6·1) 40·6 (6·3) 36·5 (4·9) 36·5 (5·8) 39·2 (5·0) 39·7 (4·7) 45·8 (5·0) 46·0 (5·7)
HADS, anxiety subscale 7·4 (4·1) 7·6 (4·0) 5·2 (2·9) 5·4 (3·3) 7·0 (3·7) 7·4 (3·7) 10·1 (4·2) 10·1 (3·8)
HADS, depression subscale 5·8 (4·1) 6·0 (4·1) 3·1 (2·7) 3·0 (2·5) 5·5 (3·3) 6·0 (3·8) 8·9 (4·3) 8·9 (3·7)
General health
Widespread pain‡ 186 (33%) 104 (37%) 33 (22%) 16 (22%) 93 (35%) 56 (43%) 60 (38%) 32 (41%)
SF12, physical component 37·0 (10·4) 36·4 (10·6) 45·9 (8·6) 46·0 (9·1) 35·7 (9·5) 35·1 (8·6) 30·8 (7·6) 29·6 (8·2)
SF12, mental component 48·2 (11·9) 47·8 (11·7) 53·7 (7·3) 53·0 (8·1) 49·6 (11·5) 48·6 (11·3) 40·6 (12·5) 41·5 (12·3)
Data are mean score (SD) or number (%). RMDQ=Roland and Morris Disability Questionnaire. PCS=Pain Catastrophizing Scale. TSK=Tampa Scale of Kinesiophobia. HADS=Hospital Anxiety and Depression Scale. 
SF12=Short Form 12. *Based on major groups 5–9 of the UK Standard Occupation Classiﬁ cation (2000) for current or most recent paid employment  (inclusive of 36 missing data [26 in intervention group and 
ten in control group]). †Responders who reported being currently in paid employment at baseline and taking time oﬀ  during the 12 months before baseline. ‡Based on the American College of Rheumatology’s 
deﬁ nition.33
Table 1: Baseline characteristics of participants randomly assigned according to treatment group in total and stratiﬁ ed according to risk group
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4·2 sessions [SD 2·1] vs 5·1 sessions [3·5]) during a 
shorter time span (47·7 days [33·0] vs 69·4 days [50·3]) 
than did participants in the control group. No serious or 
non-serious adverse events were reported. 
Overall, the reduction in RMDQ score (primary 
outcome) was larger in the intervention group than in 
the control group (ﬁ gure 2), even with conservative 
sensitivity analyses (table 2). For the primary outcome, 
All participants p value Low-risk participants p value Medium-risk participants p value High–risk participants p value
Intervention group 568 ·· 148 ·· 263 ·· 157 ··
Control group 283 ·· 73 ·· 131 ·· 79 ··
4 months
Mean change (SD)
Intervention group 4·7 (5·9) ·· 1·6 (4·4) ·· 5·3 (6·0) ·· 6·8 (6·9) ··
Control group 3·0 (5·9) ·· 0·8 (4·3) ·· 3·4 (6·1) ·· 4·4 (6·1) ··
Mean diﬀ erence* (95% CI) 1·81 (1·06 to 2·57) <0·0001 0·66 (–0·41 to 1·74) 0·2211 1·99 (0·75 to 3·22) 0·0012 2·53 (0·90 to 4·16) 0·0024
Sensitivity analysis† 1·54 (0·77 to 2·30) <0·0001 0·66 (–0·42 to 1·74) 0·2275 1·59 (0·49 to 2·69) 0·0048 2·28 (0·49 to 4·07) 0·0129
Sensitivity analysis‡ 1·83 (1·01 to 2·65) <0·0001 0·74 (–0·50 to 1·98) 0·2447 1·99 (0·73 to 3·25) 0·0021 2·57 (0·81 to 4·32) 0·0045
Eﬀ ect size§ (95% CI) 0·32 (0·19 to 0·45) <0·0001 0·19 (–0·12 to 0·51) 0·2211 0·43 (0·16 to 0·70) 0·0012 0·56 (0·20 to 0·92) 0·0024
Participants with good outcome¶
Intervention group 392 (69%) ·· 100 (68%) ·· 186 (71%) ·· 106 (68%) ··
Control group 158 (56%) ·· 42 (58%) ·· 75 (57%) ·· 40 (51%) ··
Odds ratio|| (95% CI) 1·85 (1·36 to 2·51) <0·0001 1·58 (0·83 to 3·00) 0·1618 2·00 (1·20 to 3·33) 0·0073 1·96 (1·03 to 3·71) 0·0390
Number needed to treat** (95% CI) 7·0 (13·5 to 4·9) <0·0001 9·5 (–21·8 to 4·4) 0·1618 6·5 (22·8 to 4·1) 0·0073 6·2 (135·0 to 3·5) 0·0390
12 months
Mean change (SD)
Intervention group 4·3 (6·4) ·· 1·6 (4·5) ·· 4·9 (5·9) ·· 5·9 (7·2) ··
Control group 3·3 (6·2) ·· 1·2 (4·8) ·· 3·6 (6·3) ·· 4·8 (6·3) ··
Mean diﬀ erence* (95% CI) 1·06 (0·25 to 1·86) 0·0095 0·12 (–1·13 to 1·38) 0·8456 1·33 (0·15 to 2·52) 0·0253 1·22 (–0·47 to 2·91) 0·1547
Sensitivity analysis† 1·06 (0·26 to 1·87) 0·0099 0·29 (–0·86 to 1·44) 0·6177 1·18 (0·01 to 2·34) 0·0482 1·30 (–0·54 to 3·13) 0·1653
Sensitivity analysis‡ 1·08 (0·18 to 1·98)   0·0186 0·06 (–1·37 to 1·50) 0·9298 1·35 (0·12 to 2·58) 0·0317 1·56 (–0·72 to 3·84) 0·1710
Eﬀ ect size§ (95% CI) 0·19 (0·04 to 0·33) 0·0095 0·04 (–0·33 to 0·41) 0·8456 0·29 (0·03 to 0·55) 0·0253 0·27 (–0·10 to 0·65) 0·1547
Participants with good outcome¶
Intervention group 367 (65%) ·· 98 (66%) ·· 176 (67%) ·· 93 (59%) ··
Control group 160 (57%) ·· 44 (60%) ·· 77 (59%) ·· 39 (49%) ··
Odds ratio|| (95% CI) 1·48 (1·02 to 2·15) 0·0344 1·22 (0·60 to 2·47) 0·5754 1·55 (0·93 to 2·57) 0·0874 1·57 (0·82 to 3·00) 0·1723
Number needed to treat ** (95% CI) 10·8 (206·0 to 5·8) 0·0344 21·4 (–7·9 to 5·4) 0·5754 10·0 (–56·5 to 5·1) 0·0874 9·0 (–20·2 to 4·0) 0·1723
Data are number (%), unless otherwise indicated. RMDQ=Roland and Morris Disability Questionnaire. *Mean for the intervention group minus mean for the control group (by use of linear regression adjusted for 
age, sex, baseline RMDQ, and duration of back pain). †Based on observed or available case data. ‡Based on imputed datasets with adjustment for clustering by therapist (by use of random-eﬀ ects linear 
regression modelling). §Mean diﬀ erence relative to the pooled SD of baseline scores. ¶Deﬁ ned as at least 30% change in the RMDQ score compared with baseline; the numbers represent average rounded counts 
of ﬁ ve imputed datasets. ||Odds of a good outcome in the intervention group relative to the control group (by use of binary logistic regression with adjustment for age, sex, baseline RMDQ, and duration of back 
pain). **Based on the point estimate for the proportion of patients with good outcomes in the control group and the odds ratio for good outcomes in the intervention group relative to the control group; smaller 
positive numbers for the 95% CI convey a stronger association than do larger positive numbers and smaller negative numbers indicate a greater advantage towards the control group, and therefore the number 
needed to treat does not necessarily lie within the 95% CI. 
Table 2: Mean change in scores with the Roland and Morris Disability Questionnaire (primary outcome measure) during 4-month and 12–month follow-ups 
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Figure 2: Mean change from baseline in RMDQ (primary outcome measure) scores at 4-month and 12-month follow-ups in all participants (A), low-risk participants (B), medium-risk 
participants (C), and high-risk participants (D)
RMDQ=Roland and Morris Disability Questionnaire.
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the between-group adjusted mean diﬀ erences in change 
in RMDQ scores were signiﬁ cant at 4 months and 
12 months, equating to standardised eﬀ ect sizes of 0·32 
and 0·19, respectively (table 2). 
Diﬀ erences in secondary outcome measures in favour 
of the intervention for all participants were signiﬁ cant at 
4 months for pain intensity, catastrophising, fear, anxiety, 
depression, general health (physical component), STarT 
Back Screening Tool risk reduction, and global change 
(table 3); and at 12 months for catastrophising, fear, 
depression, general health (physical component), and 
risk reduction (table 3). The patients in the intervention 
group were signiﬁ cantly more likely to be satisﬁ ed with 
treatment (data available for 4 months follow-up), and 
took fewer days oﬀ  work because of back pain (data 
available for 12 months follow-up).
Details of health-care resource use, health-care costs, 
days oﬀ  work, and health-related quality of life (EQ-5D 
scores and QALY estimates) are provided in webappendix 
p 7 for each group. The stratiﬁ ed management inter-
vention resulted in greater mean health beneﬁ t 
(0·039 additional QALYs), achieved at a lower mean 
health-care cost (cost saving £34·39; webappendix p 8), 
than the control. Similar inferences were drawn from the 
complete-case analysis (0·033 additional QALYs and a 
mean cost saving of £41·93; webappendix p 8). Figure 3 
shows the cost-eﬀ ectiveness plane for the primary 
analysis, generated from 25 000 bootstrap samples.16 The 
dominance of the stratiﬁ ed intervention (ie, greater 
beneﬁ t at lower cost) was shown in 92% of replications 
(ie, 92% of bootstrapped cost-eﬀ ect pairs were in the 
southeast quadrant).
The societal beneﬁ t from fewer work days lost because 
of back pain corresponded to a mean indirect (productivity) 
cost saving of £675 over the 12-month follow-up for the 
intervention group compared with the control group 
(webappendix p 8).
For the primary and secondary clinical outcomes, 
diﬀ erences between the intervention and control groups 
within the low-risk group indicated non-inferiority, 
although signiﬁ cantly fewer work days were lost in the 
intervention group (table 2, table 3). For the medium-risk 
and high-risk groups, the adjusted between-group mean 
diﬀ erences in RMDQ scores were signiﬁ cant at 4 months 
(table 2), but the diﬀ erence was only signiﬁ cant for the 
medium-risk group and not the high-risk group at 
12 months (table 2). One notable ﬁ nding was that the 
mean number of work days lost at 12 months was far 
fewer in the medium-risk participants in the intervention 
group than in the control group. 
All participants Low–risk participants Medium–risk participants High–risk participants
Inter-
vention 
group 
(n=568)
Control 
group 
(n=283)
Point 
estimate 
(95% CI)
p value Inter-
vention 
group 
(n=148)
Control 
group 
(n=73)
Point 
estimate 
(95% CI)
p value Inter-
vention 
group 
(n=263)
Control 
group 
(n=131)
Point 
estimate 
(95% CI)
p value Inter-
vention 
group 
(n=157)
Control 
group 
(n=79)
Point 
estimate 
(95% CI)
p value
Back pain intensity
4 months, 
mean 
change (SD)
3·2 
(2·5)
2·6
(2·4)
0·55* 
(0·23 to 
0·86)
0·0005 1·7 
(2·2)
1·5
(2·1)
0·28* 
(–0·29 to 
0·84)
0·3182 3·5 
(2·6)
2·8
(2·1)
0·58* 
(0·06 to 
1·10)
0·0200 4·2 
(2·3)
3·4
(2·9)
0·73* 
(0·04 to 
1·42)
0·0316
12 months, 
mean 
change (SD)
3·0 
(2·8)
2·8
(2·6)
0·11* 
(–0·21 to 
0·43)
0·5002 1·7 
(2·3)
1·7
(2·4)
0·10* 
(–0·51 to 
0·70)
0·7461 3·3 
(2·6)
3·0
(2·8)
0·16* 
(–0·44 to 
0·76)
0·5802 3·7 
(2·7)
3·6
(3·2)
–0·01* 
(–0·72 to 
0·70)
0·9755
STarT Back risk group
4 months ·· ·· 2·09† 
(1·40 to 
3·12)
0·0003 ·· ·· 1·16† 
(0·36 to 
3·67)
0·8021 ·· ·· 1·70† 
(0·95 to 
3·03)
0·0678 ·· ·· 3·14† 
(1·63 to 
6·06)
0·0006
Low risk 439 
(77%)
186
(66%)
·· ·· 134 
(91%)
65
(89%)
·· ·· 201 
(76%)
89
(68%)
·· ·· 104 
(66%)
32
(41%)
·· ··
Medium 
risk
103 
(18%)
70
(25%)
·· ·· 12 
(8%)
7
(10%)
·· ·· 55 
(21%)
36
(27%)
·· ·· 36 
(23%)
27
(34%)
·· ··
High risk 26 
(5%)
27
(10%)
·· ·· 2 
(1%)
1
(1%)
·· ·· 7 
(3%)
6
(5%)
·· ·· 17 
(11%)
20
(25%)
·· ··
12 months ·· ·· 1·51† 
(1·01 to 
2·25)
0·0405 ·· ·· 0·91† 
(0·31 to 
2·65)
0·8562 ·· ·· 1·51† 
(0·85 to 
2·66)
0·1525 ·· ·· 1·62† 
(0·82 to 
3·23)
0·1566
Low risk 430 
(76%)
195
(69%)
·· ·· 131 
(89%)
65
(89%)
·· ·· 204 
(78%)
94
(72%)
·· ·· 95 
(61%)
36
(46%)
·· ··
Medium 
risk
111 
(20%)
71
(25%)
·· ·· 17 
(11%)
7
(10%)
·· ·· 56 
(21%)
35
(27%)
·· ·· 38 
(24%)
29
(37%)
·· ··
High risk 27 
(5%)
17
(6%)
·· ·· 0 1
(1%)
·· ·· 3 
(1%)
2
(2%)
·· ·· 24 
(15%)
14
(18%)
·· ··
(Continues on next page)
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All participants Low–risk participants Medium–risk participants High–risk participants
Inter-
vention 
group 
(n=568)
Control 
group 
(n=283)
Point 
estimate 
(95% CI)
p value Inter-
vention 
group 
(n=148)
Control 
group 
(n=73)
Point 
estimate 
(95% CI)
p value Inter-
vention 
group 
(n=263)
Control 
group 
(n=131)
Point 
estimate 
(95% CI)
p value Inter-
vention 
group 
(n=157)
Control 
group 
(n=79)
Point 
estimate 
(95% CI)
p value
(Continued from previous page)
Global change
4 months ·· ·· 1·55† 
(1·16 to 
2·07)
0·0032 ·· ·· 1·45† 
(0·80 to 
2·60)
0·2153 ·· ·· 1·57† 
(1·04 to 
2·36) 
0·0304 ·· ·· 1·70† 
(0·98 to 
2·96)
0·0595
Much 
better
252 
(44%)
99
(35%)
·· ·· 70 
(47%)
28
(38%)
·· ·· 125 
(48%)
50
(38%)
·· ·· 57 
(36%)
21
(27%)
·· ··
Better 151
 (27%)
82
(29%)
·· ·· 38 
(26%)
23
(32%)
·· ·· 70 
(27%)
40
(31%)
·· ·· 43 
(27%)
19
(24%)
·· ··
Not better 165 
(29%)
102
(36%)
·· ·· 40 
(27%)
22
(30%)
·· ·· 68 
(26%)
41
(31%)
·· ·· 57 
(36%)
39
(49%)
·· ··
12 months ·· ·· 1·23† 
(0·95 to 
1·60)
0·1104 ·· ·· 0·80† 
(0·41 to 
1·54)
0·4812 ·· ·· 1·54† 
(0·99 to 
2·39)
0·0520 ·· ·· 1·26† 
(0·72 to 
2·21)
0·4072
Much 
better
229 
(40%)
99
(35%)
·· ·· 57 
(39%)
32
(44%)
·· ·· 116 
(44%)
46
(35%)
·· ·· 56 
(36%)
21
(27%)
·· ··
Better 121 
(21%)
63
(22%)
·· ·· 36 
(24%)
17
(23%)
·· ·· 59 
(22%)
31
(24%)
·· ·· 26 
(17%)
15
(19%)
·· ··
Not better 218 
(38%)
121
(43%)
·· ·· 55 
(37%)
24
(33%)
·· ·· 88 
(33%)
54
(41%)
·· ·· 75 
(48%)
43
(54%)
·· ··
PCS–catastrophising
4 months, 
mean 
change (SD)
6·4 
(10·8)
3·9
(10·4)
2·35* 
(0·91 to 
3·79)
0·0010 2·6 
(7·3)
1·3
(8·0)
1·10* 
(–0·82 to 
3·02)
0·2590 5·9 
(10·1)
3·6
(10·1)
1·88* 
(–0·09 to 
3·84)
0·0531 10·8 
(12·1)
6·9
(13·3)
3·91* 
(0·41 to 
7·41)
0·0242
12 months, 
mean 
change (SD)
6·1 
(10·6)
4·4
(11·4)
1·69* 
(0·37 to 
3·01)
0·0113 3·2 
(8·6)
1·6
(7·7)
1·47* 
(–0·60 to 
3·54)
0·1516 5·7 
(9·0)
3·6
(10·5)
1·74* 
(–0·11 to 
3·60)
0·0630 9·4 
(12·1)
8·1
(12·7)
1·35* 
(–1·70 to 
4·40)
0·3816
TSK–fear avoidance
4 months, 
mean 
change (SD)
5·5 
(7·0)
3·2
(6·0)
2·52* 
(1·61 to 
3·43)
<0·0001 3·5 
(7·1)
2·8
(7·3)
0·86* 
(–1·01 to 
2·73)
0·3540 5·2 
(7·9)
2·8
(5·7)
2·72* 
(1·45 to 
3·98)
<0·0001 7·9 
(8·0)
4·3
(6·0)
3·70* 
(1·70 to 
5·70)
0·0003
12 months, 
mean 
change (SD)
5·2 
(7·3)
3·3
(10·3)
2·18* 
(0·73 to 
3·63)
0·0013 3·5 
(7·2)
2·4
(9·3)
1·22* 
(–1·26 to 
3·70)
0·3030 4·9 
(7·6)
3·2
(8·2)
2·14* 
(0·23 to 
4·04)
0·0181 7·3 
(7·7)
4·3
(7·2)
3·12* 
(1·18 to 
5·06)
0·0016
HADS, anxiety subscale
4 months, 
mean 
change (SD)
1·7 
(3·6)
1·2
(4·0)
0·63* 
(0·08 to 
1·18)
0·0208 0·6 
(3·3)
0·9
(3·5)
–0·17* 
(–0·97 to 
0·62)
0·6666 1·7 
(3·8)
0·8
(3·7)
1·10* 
(0·33 to 
1·86)
0·0039 2·8 
(4·3)
2·2
(4·5)
0·56* 
(–0·57 to 
1·69)
0·3155
12 months, 
mean 
change (SD)
1·3 
(3·9)
1·0
(4·4) 
0·45* 
(–0·10 to 
1·01)
0·1035 0·5 
(3·2)
0·8
(4·0)
–0·13* 
(–1·22 to 
0·96)
0·8023 1·3 
(4·2)
0·6
(4·2)
0·88* 
(0·08 to 
1·68)
0·0283 2·1 
(4·5)
1·7
(5·0)
0·28* 
(–1·14 to 
1·71)
0·6783
HADS, depression subscale
4 months, 
mean 
change (SD)
1·7 
(3·7)
1·1
(3·3)
0·71* 
(0·26 to 
1·15)
0·0018 0·3 
(3·2)
0·2
(3·3)
0·09* 
(–0·69 to 
0·88)
0·8086 1·7 
(3·6)
1·2
(3·5)
0·79* 
(0·13 to 
1·45)
0·0193 3·0 
(4·3)
1·9
(3·8)
1·13* 
(0·16 to 
2·09)
0·0223
12 months, 
mean 
change (SD)
1·4 
(4·1)
0·9
(4·0)
0·62* 
(0·07 to 
1·17)
0·0227 0·2 
(3·3)
0·2
(3·5)
–0·03* 
(–0·92 to 
0·86)
0·9494 1·3 
(3·7)
1·0
(3·8)
0·63* 
(–0·10 to 
1·36)
0·0863 2·7 
(4·7)
1·5
(4·5)
1·21* 
(0·02 to 
2·40)
0·0413
SF12, physical component
4 months, 
mean 
change (SD)
–7·5 
(13·0)
–5·2
(13·3)
–2·83* 
(–4·62 to 
–1·05)
0·0010 –3·2 
(9·6)
–1·8
(9·7)
–1·50* 
(–3·89 to 
0·89)
0·2137 –9·1 
(11·7)
–6·4
(10·7)
–3·27* 
(–5·51 to 
–1·03)
0·0037 –8·9 
(15·1)
–6·4
(15·8)
–3·13* 
(–7·50 to 
1·23)
0·1215
12 months, 
mean 
change (SD)
–7·5 
(11·3)
–5·2
(10·9)
–2·93* 
(–4·31 to 
–1·56)
<0·0001 –4·0 
(9·7)
–2·4
(10·1)
–1·70* 
(–4·25 to 
0·85)
0·1825 –8·8 
(11·5)
–5·7
(11·7)
–3·74* 
(–6·02 to 
–1·46)
0·0012 –8·6 
(12·2)
–6·8
(13·1)
–2·46* 
(–5·90 to 
0·97)
0·1464
SF12, mental component
(Continues on next page)
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Discussion
A stratiﬁ ed management approach in which prognostic 
screening and treatment targeting were combined 
resulted in improved primary care eﬃ  ciency, leading to 
higher health gains for patients with back pain than did 
existing non-stratiﬁ ed best care. Signiﬁ cant improve-
ments were not only noted in the primary outcome 
measure (disability) at both 4-month and 12-month 
follow-ups, but also for a range of secondary outcome 
measures, including physical and emotional functioning, 
pain intensity, quality of life, days oﬀ  work, global 
improvement ratings, and treatment satisfaction. 
Although the eﬀ ect sizes for the targeted intervention 
were similar to other primary care trials,6–9 the additional 
beneﬁ t provided by stratiﬁ ed care is noteworthy when 
the size of the disability reduction in the control group is 
considered. Mean RMDQ change scores in the control 
group were larger at 4 months and 12 months than the 
within-group change of 2·5 points generally judged to 
be a clinically meaningful change,34 and also larger than 
reductions noted in the active intervention groups of 
other trials (panel).6,7,9 
From an economics perspective, the stratiﬁ ed manage-
ment approach was associated with improvements in 
health-related quality of life (QALYs), a reduction in 
health-care use, and fewer days oﬀ  work related to back 
pain. Health beneﬁ ts and cost savings attributable to the 
stratiﬁ ed intervention might have been underestimated; 
resource use outside the study clinic sessions was less 
common and the between-group diﬀ erence in quality of 
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Figure 3: Cost-eﬀ ectiveness plane for the comparison of the stratiﬁ ed management approach (intervention 
group) with current best practice (control group), based on 25 000 bootstrapped cost-eﬀ ect pairs
QALYs=quality-adjusted life years.
All participants Low–risk participants Medium–risk participants High–risk participants
Inter-
vention 
group 
(n=568)
Control 
group 
(n=283)
Point 
estimate 
(95% CI)
p value Inter-
vention 
group 
(n=148)
Control 
group 
(n=73)
Point 
estimate 
(95% CI)
p value Inter-
vention 
group 
(n=263)
Control 
group 
(n=131)
Point 
estimate 
(95% CI)
p value Inter-
vention 
group 
(n=157)
Control 
group 
(n=79)
Point 
estimate 
(95% CI)
p value
(Continued from previous page)
4 months, 
mean 
change (SD)
–2·1 
(11·3)
–2·1
(11·0)
–0·16* 
(–1·63 to 
1·32)
0·8327 0·5 
(12·4)
–1·0
(10·2)
0·96* 
(–1·68 to 
3·60)
0·4640 –1·5 
(10·4)
–1·1
(12·0)
–0·80* 
(–2·92 to 
1·31)
0·4497 –5·5 
(12·5)
–4·8
(14·3)
–0·27* 
(–3·98 to 
3·45)
0·8811
12 months, 
mean 
change (SD)
–1·7 
(13·0)
–1·2
(13·4)
–0·69* 
(–2·39 to 
1·01)
0·4050 1·3 
(10·7)
–0·4
(9·9)
1·18* 
(–1·12 to 
3·49)
0·3124 –1·2 
(12·3)
–0·1
(12·7)
–1·53* 
(–3·62 to 
0·55)
0·1468 –5·5 
(13·8)
–3·6
(13·8)
–1·31* 
(–5·04 to 
2·43)
0·4682
Work loss‡
Days oﬀ  
work, mean 
(SD)
4·4 
(21·2)
12·2
(35·1)
2·76§ 
(2·52 to 
3·01)
<0·0001 0·4 
(1·2)
3·0
(11·9)
7·06§ 
(4·28 to 
11·6)
<0·0001 4·1 
(15·8)
18·4
(47·2)
5·17§ 
(4·52 to 
5·92)
<0·0001 9·9 
(35·4)
10·6
(18·2)
1·46§ 
(1·24 to 
1·72)
<0·0001
Satisfaction 
with care¶
·· ·· 1·98† 
(1·45 to 
2·70)
<0·0001 ·· ·· 1·24† 
(0·68 to 
2·25)
0·4784 ·· ·· 2·15† 
(1·35 to 
3·40)
0·0013 ·· ·· 3·18† 
(1·68 to 
6·00)
0·0005
Very satisﬁ ed 166/416 
(40%)
46/197
(23%)
·· ·· 30/106 
(28%)
14/56
(25%)
·· ·· 87/197 
(44%)
22/91
(24%)
·· ·· 49/113 
(43%)
10/50
(20%)
·· ··
Quite 
satisﬁ ed’
139/416 
(33%)
81/197
(41%)
·· ·· 33/106 
(31%)
21/56
(38%)
·· ·· 63/197 
(32%)
39/91
(43%)
·· ·· 43/113 
(38%)
21/50
(42%)
·· ··
Not satisﬁ ed 111/416 
(27%)
70/197
(36%)
·· ·· 43/ 106 
(41%)
21/56
(38%)
·· ·· 47/197 
(24%)
30/91
(33%)
·· ·· 21/113 
(19%)
19/50
(38%)
·· ··
Data are number (%), unless otherwise indicated. PCS=Pain Catastrophizing Scale. TSK=Tampa Scale of Kinesiophobia. HADS=Hospital Anxiety and Depression Scale. SF12=Short Form 12. RMDQ=Roland and 
Morris Disability Questionnaire. *Mean diﬀ erence—ie, mean for the intervention group minus mean for the control group (by use of linear regression adjusted for age, sex, baseline score, baseline RMDQ, and 
duration of back pain). †Odds ratio represents the proportional odds in terms of ordered response categories for the intervention group relative to the control group (by use of ordinal logistic regression adjusted 
for age, sex, baseline RMDQ, and duration of back pain). ‡Analysis of time oﬀ  work (days) is based on a total subsample of 298 of 567 responders who reported being currently employed at 12 months follow-up, 
and relates to leave due to low back pain during the period between baseline and follow-up at 12 months. §Incidence rate ratio for the extra work days lost in the control group relative to the intervention group 
(by use of Poisson regression adjusted for age, sex, baseline RMDQ, and duration of back pain). ¶Analysis was based on 613 responders to the question about satisfaction with care at 4 months follow-up: 416 in 
the intervention group and 197 in the control group.
Table 3: Summary data for secondary outcome measures at follow-ups of 4 months and 12 months
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life was greater at 12 months than at 4 months. The 
potential for long-term economic beneﬁ ts lends further 
support that a stratiﬁ ed management approach provides 
value for money.
Use of the screening method resulted in important 
diﬀ erences in the pattern of treatment referral between 
the groups. Outcomes in the low-risk group were 
non-inferior despite far less low-risk intervention patients 
(7%) having a referral for further treatment than the low-
risk controls (49%) referred for an average of ﬁ ve 
physiotherapy sessions. This ﬁ nding was in keeping 
with our theory that a substantial proportion of referrals 
based on clinical judgement alone (controls) might be 
unnecessary and that many low-risk patients are receiving 
unnecessary treatment in current practice.35 By contrast, 
113 (40%) medium-risk and 91 (32%) high-risk patients 
in the control group were not oﬀ ered further treatments, 
which is likely to have contributed to their signiﬁ cantly 
smaller reductions in disability than in the medium-risk 
and high-risk patients in the intervention group at 
4 months and 12 months. Our interpretation of these 
ﬁ ndings is that, without systematic prognostic screening 
to assist treatment referral, many medium-risk and high-
risk patients are potentially being denied access to more 
sophisticated treatments that are likely to improve their 
clinical outcomes. This issue is perhaps most important 
for patients classiﬁ ed as high risk (28%) who showed 
signiﬁ cant, substantial reductions in disability (RMDQ) 
at 4 months (mean change 6·8; table 2). Although these 
results lend some support to the use of psychologically 
informed physiotherapy for patients with psychological 
distress,7 further research is needed to establish if these 
short-term beneﬁ ts can be sustained, because the 
diﬀ erence between the high-risk groups at 12 months 
(5·9) was not signiﬁ cant. Noteworthy is that, with the 
design used for this pragmatic clinical trial, we are not 
able to ascertain whether risk-group level beneﬁ ts were 
the result of improvements in referral patterns, or to 
improvements in the content or quality of the follow-up 
physiotherapy sessions. Nevertheless, our ﬁ ndings 
support the clinical eﬀ ectiveness and cost-eﬀ ectiveness 
of a combined stratiﬁ ed management approach.
The strengths of this trial include high internal valid-
ity, with remote randomisation, treatments delivered 
according to protocols, eﬀ ective masking of assessors, 
consistent ﬁ ndings for several disparate outcomes, and a 
sample size large enough to enable a separate 
examination of the eﬀ ectiveness within the low-risk, 
medium-risk, and high-risk groups. Another strength is 
that the sensitivity analyses, including a conservative 
approach with adjust ment for any potentially unequal 
therapist expertise or skills (therapist eﬀ ects),36 did not 
change the clinical or economic ﬁ ndings. Limitations 
included a greater than anticipated loss to follow-up and 
a slight imbalance in attrition between the groups, 
addressed through extended recruitment and imputation. 
Also because delivery of physiotherapy was complex, 
with a variable number of sessions by a variable number 
of diﬀ erent physiotherapists, the random-eﬀ ect adjust-
ment for the therapist could only be applied in the 
adjustment for diﬀ erences with a designated main 
therapist. Additional between-group variability might 
have remained unadjusted.
The wider implications of the results of this trial are 
that patients’ outcomes can be improved with a stratiﬁ ed 
approach to primary care management of low back pain. 
Results from primary care cohort studies18 suggest that 
the low-risk group might represent as many as 56% of all 
back pain consultations with the family doctor. Hence, 
substantial reductions could have occurred in health-care 
use and time oﬀ  work if stratiﬁ ed primary care were 
implemented. We recognise the challenges in imple-
menting these ﬁ ndings in clinical services, and that our 
results might not be generalisable to other health-care 
settings or musculoskeletal complaints. Our research 
group and others are investigating implementing 
stratiﬁ ed management into routine primary care in the 
Panel: Research in context
Systematic review
Previous reports of relevant large randomised controlled trials, 
international guidelines, and meeting abstracts were searched 
with Ovid Medline up to May, 2011, using exploded Medline 
Medical Subject Headings and free text terms for “back pain” in 
combination with “primary health care”. This search was 
restricted to English language papers and the few Medline 
clinical queries were used to restrict the search to studies of 
treatments only (to achieve maximum speciﬁ city). The 
evidence suggests that sophisticated treatments (such as 
manual treatments and exercise) are more eﬀ ective than are 
minimal packages of care but similar to each other.10 There are 
no trials of methods for tailoring treatment to individual 
patients or investigation of the clinical eﬀ ectiveness and 
cost-eﬀ ectiveness of using prognostic screening protocols to 
help identify patients to be targeted with referral beyond 
minimum treatment.10
Interpretation
This trial is unique in that the results show the role of 
system-wide changes with a stratiﬁ ed approach to improve 
outcomes in patients with low back pain and reduce 
health-care costs. Although the eﬀ ect sizes were similar to 
those of other trials,6–9 these improvements are noteworthy 
because improvements in the control group were substantial 
and similar to those of the active interventions in other clinical 
trials;6–9 the control included sophisticated treatments, not 
just minimum care; and the stratiﬁ ed intervention was highly 
cost eﬀ ective. Although referral rates with stratiﬁ ed 
management were higher, these health-sector costs were 
outweighed by savings due to reductions in referral of low-risk 
patients and overall use of health-care resources during the 
follow-up. The results of this trial have important implications 
for commissioners and providers of services for back pain.
Articles
1570 www.thelancet.com   Vol 378   October 29, 2011
UK,37 with further collaborative research in the USA, 
Denmark, and the Netherlands. 
For many years, the potential for targeting treatment 
has been emphasised as a research priority for back 
pain.38 The results of this trial provide the ﬁ rst evidence 
that a stratiﬁ ed management approach to target the 
provision of primary care signiﬁ cantly improves patient 
outcomes and is associated with substantial economic 
beneﬁ ts compared with current best practice. As such, 
the ﬁ ndings of this study represent an important advance 
in primary care management of back pain, and have 
important implications for commissioners and providers 
of services for back pain.
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